Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.

Astrid O LeechSri HariKrishna VellankiEmily J RutherfordAoife KeoghHanne JahnsLance HudsonNorma O'DonovanSiham SabriBassam AbdulkarimKatherine M SheehanElaine W KayLeonie S YoungArnold D K HillYvonne E SmithAnn M Hopkins

Published in: Breast cancer research : BCR (2018)

Collectively, our data suggest a novel model whereby increased expression and cleavage of JAM-A drive tumorigenic behavior and act as a biomarker and potential therapeutic target for resistance to HER2-targeted therapies.

Keyphrases

poor prognosis
dna binding
electronic health record
binding protein
escherichia coli
biofilm formation
machine learning
deep learning